MATE™: NEXT GENERATION ANTIBODY CONJUGATION TECHNOLOGY
Multimodal Antibody Therapy Enhancers or (MATE™) are a next-generation antibody conjugation technology that enables site-directed pairing with off-the-shelf therapeutic monoclonal antibodies (mAbs), or therapeutic commercial immunoglobulin (IG) pooled from donors.
![Biohaven MATE - Multimodal Antibody Therapy Enhancers](https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Biohaven-MATE-Multimodal-Antibody-Therapy-Enhancers.png)